111 Capital Makes New Investment in Amicus Therapeutics, Inc. $FOLD

111 Capital bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,355 shares of the biopharmaceutical company’s stock, valued at approximately $77,000.

Other large investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its holdings in Amicus Therapeutics by 53.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 8,567 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in Amicus Therapeutics in the first quarter worth about $1,533,000. Invesco Ltd. raised its holdings in Amicus Therapeutics by 4.1% in the first quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock worth $21,717,000 after purchasing an additional 105,856 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in Amicus Therapeutics by 46.6% in the first quarter. Rice Hall James & Associates LLC now owns 2,010,104 shares of the biopharmaceutical company’s stock worth $16,402,000 after purchasing an additional 639,024 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Amicus Therapeutics by 47.4% in the first quarter. Victory Capital Management Inc. now owns 257,088 shares of the biopharmaceutical company’s stock worth $2,098,000 after purchasing an additional 82,691 shares in the last quarter.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $8.16 on Wednesday. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65. The company’s 50 day moving average is $7.62 and its 200 day moving average is $6.90. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The company has a market cap of $2.52 billion, a PE ratio of -67.99 and a beta of 0.56.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on FOLD shares. Weiss Ratings restated a “sell (e+)” rating on shares of Amicus Therapeutics in a report on Saturday, September 27th. Morgan Stanley upgraded shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a report on Thursday, July 17th. Wall Street Zen upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, September 20th. Finally, Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Thursday, September 18th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.78.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.